Livagen vs Ovagen
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Lys-Glu-Asp-Ala, KEDA
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
Also: Glu-Asp-Leu, EDL
Ovagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
Key Comparison Insights
- Both peptides belong to the Bioregulators category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Livagen | Ovagen |
|---|---|---|
| Category | Bioregulators | Bioregulators |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The bioregulator hypothesis is that these very short peptides can enter cells and even the nucleus, where they interact with DNA or chromatin and influence which genes are read. For Livagen specifically, in-vitro work reported decondensation of pericentromeric heterochromatin (the densely coiled, mostly silent regions of chromosomes) and reactivation of ribosomal genes in cells from elderly donors. The idea is that aging packs chromatin tighter and shuts genes down, and that KEDA helps unpack it to restore gene activity. This remains a proposed mechanism rather than an established one, and how a four amino acid peptide would achieve such targeted epigenetic effects is not well explained by mainstream molecular biology. | The general bioregulator hypothesis holds that di- and tripeptides like EDL are small enough to be carried into cells through peptide transporters (the PEPT1 and PEPT2 systems that normally absorb dietary peptide fragments), after which they are proposed to influence transcription in a tissue-selective manner. For Ovagen the claimed targets are hepatocytes (liver cells) and gastrointestinal epithelium. This is a proposed model extrapolated from the broader Khavinson peptide research, not a mechanism that has been directly and independently demonstrated for Ovagen itself. As with the other bioregulators, the leap from "short peptide enters cell" to "specifically reprograms organ-level gene expression" is not supported by mainstream molecular evidence. |
| Common Dosing | 10-20 mg daily Once or twice daily | 10-20 mg daily Once or twice daily |
| Administration | Oral capsules or sublingual | Oral capsules or sublingual |
| Typical Duration | 10-30 day cycles | 10-30 day cycles |
| Best Time to Take | Morning on empty stomach | Morning on empty stomach |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The cited evidence for Livagen is narrow and comes overwhelmingly from Khavinson, Lezhava, and collaborators. The key study, published in the Bulletin of Experimental Biology and Medicine in 2002, exposed cultured lymphocytes from old people to Livagen and reported activation of ribosomal genes and decondensation of structural heterochromatin. Similar chromatin-reactivation effects were described across a set of related peptides (Vilon, Epitalon, Prostamax, Cortagen) in the same line of work. These are small, mechanistic, cell-level observations, not clinical outcomes. There are no registered randomized human trials of Livagen, no evidence it improves liver disease or any condition in people, and independent replication outside the originating institutions is essentially absent. Most online product descriptions extrapolate far beyond what the actual data shows. Treat Livagen as an experimental research compound with low-quality evidence. | Ovagen is one of the more obscure entries in this category and the verifiable research is sparse. The broader peptide-bioregulator literature, much of it from a single Russian institute, reports gene-expression and chromatin effects for canonical members like Epitalon (AEDG) and Vilon (KE), and Ovagen is described as belonging to that same general class. But specific, independently reproduced studies on EDL itself are hard to find, and the claims that it reduces liver fibrosis or protects gut mucosa trace back to product marketing rather than controlled experiments. There are no registered human clinical trials of Ovagen and no high-quality evidence that it treats any liver or digestive condition in people. Anyone evaluating it should understand it as an unproven research compound whose marketed benefits far outrun the published science. |
Frequently Asked Questions: Livagen vs Ovagen
What is the difference between Livagen and Ovagen?
Livagen is a bioregulators peptide that livagen is a synthetic tetrapeptide (lys-glu-asp-ala, or keda) from the family of short "peptide bioregulators" developed by vladimir khavinson's group in st. petersburg, marketed in connection with liver and immune function. the proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism. Ovagen is a bioregulators peptide that ovagen is a synthetic ultra-short peptide, marketed as the tripeptide glu-asp-leu (edl), and grouped with the khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. the honest picture: there is very little verifiable scientific data on ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Livagen or Ovagen?
Neither is universally "better" - the choice depends on your specific goals. Livagen is typically used for bioregulators purposes, while Ovagen is used for bioregulators. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Livagen and Ovagen be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Livagen and Ovagen together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.